Impact BioMedical Inc.
IBO
$0.8569
-$0.0731-7.86%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 65.29% | -26.86% | 28.78% | 70.69% | 55.36% |
| Depreciation & Amortization | 0.36% | -0.36% | 0.00% | 0.72% | 0.36% |
| Other Operating Expenses | 650.00% | 200.00% | 0.00% | -- | -- |
| Total Operating Expenses | 4.55% | -37.90% | -3.99% | 10.37% | 21.26% |
| Operating Income | -4.55% | 37.90% | 3.99% | -10.37% | -21.26% |
| Income Before Tax | 460.32% | 21.14% | -17.55% | 75.96% | -20.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 460.32% | 21.14% | -17.55% | 62.54% | 47.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -60.00% | -126.32% | -81.25% | 550.00% | -77.61% |
| Net Income | 465.49% | 19.33% | -46.42% | 63.27% | 46.43% |
| EBIT | -4.55% | 37.90% | 3.99% | -10.37% | -21.26% |
| EBITDA | -4.46% | 37.87% | 4.00% | -50.80% | -76.36% |
| EPS Basic | 2,337.58% | -469.87% | -934.41% | 12.16% | 46.43% |
| Normalized Basic EPS | 2,363.73% | -475.26% | -1,125.00% | -155.45% | -32.47% |
| EPS Diluted | 400.00% | -350.00% | -900.00% | 0.63% | 35.06% |
| Normalized Diluted EPS | 461.76% | -475.26% | -1,125.00% | -155.45% | -32.47% |
| Average Basic Shares Outstanding | -83.68% | -85.82% | -85.81% | -58.15% | 0.00% |
| Average Diluted Shares Outstanding | 2.13% | -85.82% | -85.81% | -58.15% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
